Ochsner Health COVID-19 SharePoint Site "Safety On Site" Click here to enter an S.O.S.
Medications listed are available on OH EPIC Formulary, unless otherwise noted.
Not all formulary medications are available at each facility. Please refer to your local pharmacy for available inventory.
Search results for:

aflibercept ophthalmic

aflibercept ophthalmic
Drug Name Form Strength Infusion Center Available Restricted Non-formulary Ambulatory Available Interchange REMS
Eylea SOLUTION, INTRAVITREAL 40 mg/mL        
Eylea HD SOLUTION, INTRAVITREAL 114.3 mg/mL        
VIEW MORE Vascular Endothelial Growth Factor Antagonists
CLASS
525600
Additional Information and Links

OH Epic Formulary, available via order set, restricted to:

  • Indication: treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR)
  • Service line: Ophthalmology
  • Formulary location: Outpatient/Ambulatory
  • Service location: Clinic
  • Patient population: Adult
  • Prior authorization required: Yes
  • Restriction/criteria of use (all will apply unless specified):
    • Confirmed diagnosis of treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), or diabetic retinopathy (DR)
    • Failure, contraindication, or intolerance to other intravitreal bevacizumab (Avastin)
    • Patient is stable on aflibercept (Eylea) therapy
    • Will not be used concurrently with other ophthalmic VEGF inhibitors (e.g., aflibercept (Eylea), ranibizumab (Lucentis), bevacizumab (Avastin), faricimab-svoa (Vabysmo))
    • Patient does not have uncontrolled glaucoma, ocular or periocular infections and/or active ocular inflammation
Last updated: Jan. 27, 2025
Rhazdrugs aflibercept ophthalmic

This site is intended for the staff of Ochsner Health. While others may view accessible pages, Ochsner Health makes no warranty, express or implied, as to the use of this information outside of Ochsner Health.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved